Expected to commence next year, Cynata along with leading transplant centre Leiden University Medical Center (LUMC) in the Netherlands, will collaborate on a new clinical trial in patients who have received a kidney transplant. The trial will investigate Cynata’s MSCs as a treatment for renal graft rejection and to potentially reduce the requirement for anti-rejection drugs.